Dr. Min is a board-certified neurologist and physician-scientist with an MD from Cornell University Medical College and PhD from The Rockefeller University. He left academia to develop new therapies primarily for neurological patients, first in large pharma at Merck for almost 8 years and then in the biotechnology industry. Most recently he served one year as Chief Medical Officer and interim CEO for most of that time at Longeveron, a NASDQ-listed company specializing in the development of Mesenchymal Stem Cells for a variety of conditions.

During the first wave of COVID-19 in New York City, he put on his white coat and volunteered to treat patients in the ER during April and May 2020 at Columbia Presbyterian Medical Center in Washington Heights.

Dr. Min has expertise across Phase 1 to Phase 3 clinical studies, with particular strength in Phase 1 studies from early development such as SAD/MAD studies to late-stage Phase 1 studies such as Thorough QT Safety Studies, drug-drug interaction studies, and formulation studies. His successful experience navigating the approval of Bridion (sugammadex) at Merck Research Laboratories, a drug requiring four submissions before approval, affords him a deep understanding of clinical trial compliance and the regulatory approval process.